Trial Profile
A Phase 1a/1b Trial in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma to Determine the Safety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, a Fenretinide Phospholipid Suspension (12.5 Mg/mL) for Intravenous Infusion
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 02 Apr 2025
Price :
$35
*
At a glance
- Drugs Fenretinide (Primary)
- Indications Anaplastic large cell lymphoma; Cutaneous T-cell lymphoma; Follicular lymphoma; Mycosis fungoides; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Sezary syndrome; Squamous cell cancer; T-cell lymphoma
- Focus Adverse reactions; First in man
- Sponsors SciTech Development
- 13 Jan 2025 According to a SciTech Development media release, Patient Enrollment is Complete in Phase 1a Accelerated Trial and the trial begins detailed evaluation of clinical activity and response rates in T-cell lymphomas. and actively underway at nine renowned medical centers across the country, To determine the recommended treatment dose (RTD) to evaluate disease activity and response rates in the follow-on Phase 1b.
- 03 Dec 2024 According to a SciTech Development media release, SciTech is preparing to progress to the next phase of the T-cell NHL study and plans to enroll approximately 45 additional patients.
- 03 Dec 2024 The accelerated According to a SciTech Development media release, Phase 1a portion is nearing completion and The trial is activated and enrolling at 8 prestigious cancer institutions across the U.S.